Biotechnology, Pharmaceuticals & Genetics Industry Market Research

Competitive Intelligence, Business Analysis, Forecasts, Market Size, Trends, Companies, Statistics

Available Data Services: Custom Research Projects, Database Subsription or PDF eBooks

Industry Overview
Contents/Key Findings
Industry Statistics
Top companies
Industry trends

Biotechnology, Pharmaceuticals & Genetics OVERVIEW

Biotechnology can be defined as the use of living organisms (such as bacteria), biological processes or biological systems to create a desired end-result or end-product. Prim…

Biotechnology can be defined as the use of living organisms (such as bacteria), biological processes or biological systems to create a desired end-result or end-product. Primary markets for biotechnology include: 1) Agriculture, where genetically modified seeds are now in wide use in many nations. These seeds deliver plants that have can much higher crop yields per acre, and often have qualities such as disease-resistance, resistance to herbicides and drought-resistance. 2) The manufacture of enzymes, including enzymes used in food processing (such as the making of certain dairy products) and in converting organic matter into ethanol for fuel. 3) Pharmaceuticals, where biotechnology creates such therapies as antibodies, interleukins and vaccines based on living organisms (as opposed to the chemical compounds that make up traditional drugs) that can target specific cellular conditions, often with dramatic results (such as the drug Keytruda that famously fought cancer for former U.S. President Jimmy Carter).

Biotechnology is a modern word that describes a very old science. For example, bio-enzymes have always been essential in the production of cheese. The modern difference is that much of the world’s cheese production today utilizes a bio-engineered version of an enzyme called microbial chymosin. This chymosin is made by cloning natural genes into useful bacteria. Another example: For thousands of years, mankind has used naturally occurring microbes to convert fruit juices into wine.

The Coronavirus pandemic provided a massive boost to the biotech industry. Around the world, biopharmaceutical firms poured an immense effort into research that might lead to a greater understanding of the virus, how to prevent it and how to cure it. Much of this research effort was fueled by emergency injections of government funding.

Genetically engineered drugs, or “biotech” drugs, represent a rapidly growing portion of the global prescription drugs market, which will be boosted by the fact that generic (bioequivalent) biotech drugs are gaining approval. The U.S. Centers for Medicare & Medicaid Services (CMS) forecast called for prescription drug purchases in the U.S. to total about $463.6 billion during 2024, representing about $1,370 per capita. That projected total is up from only $200 billion in 2005 and a mere $40 billion in 1990.

Estimates of the size of the drugs market vary by source. Plunkett Research forecast the global pharmaceuticals market at $1.8 trillion for 2024. By 2027, American drug purchases alone may top $576.7 billion, according to the CMS, thanks to a rapidly aging U.S. population, increased access to insurance and the continued introduction of expensive new drugs.

China is the second-largest pharmaceuticals market in the world after the U.S. according to IQVIA. Spending on drugs in China during 2023 reached $169 billion and is expected to reach approximately $194 billion by 2027. Also in 2023, U.S. pharmaceutical exports to China reached $9.9 billion according to the United Nations COMTRADE database.

Advanced generations of drugs developed through biotechnology continually enter the marketplace. The results may be very promising for patients, as a technology-driven tipping point of medical care is approaching where drugs that target specific genes and proteins may eventually become widespread. However, it continues to be difficult and expensive to introduce a new drug in the U.S.

According to FDA figures, 55 new molecular entities (NMEs) and new biotech drugs (BLAs) were approved in the U.S. during 2023. These NMEs are novel, new active substances that are categorized differently from “NDAs” or New Drug Applications. NDAs may seek approval for drugs based on combinations of substances that have been approved in the past. Also, a large number of generic drug applications are being approved each year. That is, an application to manufacture a drug that was created as a brand name and has now lost its patent so that competing firms may seek FDA approval to manufacture it.

In R&D, one of the most promising uses for AI lies in identifying and testing chemical compounds that have potential to become new drug therapies—possibly cutting years and millions of dollars from the process. All major drug companies, including Astra Zeneca, are investing in their AI capabilities in the lab.

Dozens of exciting biotech drugs that target specific genes are seeking regulatory approval. Many of these drugs are for the treatment of specific forms of cancer. In a few instances, doctors are making treatment decisions based on a patient’s personal genetic makeup. (This strategy is often referred to as personalized medicine.) New breakthroughs in genetically targeted drugs occur regularly. A drug for certain patients who suffer from the skin cancer known as melanoma is a good example. Zelboraf, developed by drug firms Roche Holding and Daiichi Sankyo, will dramatically aid melanoma patients who are shown through genetic tests to have a mutated gene called BRAF. In trials, about 50% of such patients saw their tumors shrink, compared to only 5.5% of patients who received traditional chemotherapy.

New Drug Application Categories

Applications for drug approval by the FDA fall under the following categories:

BLA (Biologics License Application): An application for approval of a drug synthesized from living organisms. That is, they are drugs created using biotechnology. Such drugs are sometimes referred to as biopharmaceuticals.

NME (New Molecular Entity): A new chemical compound that has never before been approved for marketing in any form in the U.S.

NDA (New Drug Application): An application requesting FDA approval, after completion of the all-important Phase III Clinical Trials, to market a new drug for human use in the U.S. The drug may contain active ingredients that were previously approved by the FDA.

Biosimilars (generic biotech drugs): A term used to describe generic versions of drugs that have been created using biotechnology. Because biotech drugs (“biologics”) are made from living cells, a generic version of a drug may not be biochemically identical to the original branded version of the drug. Consequently, they are described as “biosimilars” or “follow-on biologics” to set them apart.

Priority Reviews: The FDA places some drug applications that appear to promise “significant improvements” over existing drugs for priority approval, with a goal of returning approval within six months.

Accelerated Approval: A process at the FDA for reducing the clinical trial length for drugs designed for certain serious or life-threatening diseases.

Fast Track Development: An enhanced process for rapid approval of drugs that treat certain life-threatening or extremely serious conditions. Fast Track is independent of Priority Review and Accelerated Approval.

Personal genetic codes are becoming less expensive and more widely attainable. Today, the cost of decoding the most important sections of the human genome for an individual patient has dropped dramatically.

Although total drug expenditures are currently small in developing nations such as India, China and Brazil, they have tremendous potential over the mid-term. This means that major international drug makers will be expanding their presence in these nations. However, it also means that local drug manufacturers have tremendous incentive to invest in domestic research and marketing.

The Coming BioIndustrial Era:

Some of the most exciting developments in the world of technology today are occurring in the biotech sector. These include advances in agricultural biotechnology, the convergence of nanotechnology and information technology with biotech and breakthroughs in synthetic biotechnology.

The rapidly growing worldwide base of biotechnology knowledge has the potential to create a new “bioindustrial era.” For example, scientists’ ability to capture refinable oils from algae and other organisms (organisms that remove carbon from the atmosphere as they grow) may eventually create a new source of transportation fuel.

The use of enzymes in industrial processes may enable us to bioengineer a long list of highly desirable substances at modest cost. The result could easily be a lower carbon footprint for many industrial processes, less industrial and residential waste to deal with and a significant increase in yields in chemicals, coatings, food and other vital sectors. DuPont’s acquisition of global enzyme leader Danisco is a good indicator of the looming era of bioindustrial advancements, as DuPont made a $5.8 billion bet that it can help a vast variety of manufacturers to achieve significant product enhancements and efficiencies.

Source: Plunkett Research, Ltd.

Significant ethical issues face the biotech industry as it moves forward. They include, for example, the ability to determine an individual’s likelihood to develop a disease in the future, based on his or her genetic makeup today; the potential to harvest replacement organs and tissues from animals or from cloned human genetic material; and the ability to genetically alter the basic foods that we eat. These are only a handful of the powers of biotechnology that must be dealt with by society. Watch for intense, impassioned discussion of such issues and a raft of governmental regulation as new technologies and therapies emerge.

Another breakthrough in gene therapy is CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats). The technology focuses on the use of a DNA-cutting protein that is guided by an RNA molecule, targeted at a specific gene. This technology enables a scientist to quickly and easily edit or re-engineer specific bits of DNA. A defective gene can be precisely edited within the laboratory, and then reintroduced to a patient's body as a form of gene therapy with far more accuracy than previous gene therapies. CRISPR is sometimes referred to as “genetic editing,” and it is considered to be a very significant breakthrough. Practical applications may include treatments or even cures for sickle-cell anemia, HIV and cystic fibrosis. Libraries of CRISPRs have been created by researchers at MIT that account for nearly all human genes. CRISPR is also being utilized to modify seeds and plants for agricultural use.

The biggest single issue may be privacy. Who should have access to your personal genetic records? Where should they be stored? How should they be accessed? Can you be denied employment or insurance coverage due to your genetic makeup?

Global Factors Boosting Biotech Today:

1) A rapid aging of the population in nations including the EU, much of Asia and the U.S., such as millions of surviving Baby Boomers who are entering senior years in rising numbers and require a growing level of health care are boosting demand for drugs. A significant portion of that care may be in the form of biotech drugs.

2) Major pharmaceuticals firms are paying top prices to acquire young biotech drug companies that own promising drugs.

3) A very significant market exists for genetically engineered agricultural seeds (“Agribio”), with farmers in dozens of nations planting genetically modified seeds.

4) Aggressive investment is ongoing in biotechnology research in Singapore, China and India, often with government sponsorship—for example, Singapore’s massive Biopolis project.

5) Very promising research into synthetic biology is showing good results.

6) Dramatic decreases in the cost of personal genetic studies are a big boost to personalized medicine.

7) Highly advanced biotech technologies known as gene therapies are slowly beginning to prove their ability to cure patients.

8) A focus on the discovery and manufacture of new drugs (“orphan drugs”) that impact rare diseases or relatively small portions of the population is increasing.

9) The advent of the genetic engineering process known as CRISPR is enabling scientists to alter cells and repair defective cells. This has profound potential in both human and animal health therapies.

10) CRISPR also has major potential to modify agricultural seeds and plants through gene editing.

11) Artificial Intelligence (AI) is dramatically speeding up and expanding scientists’ ability to discover and test new drug compounds and therapies. AI also makes it much easier to identify additional uses for drugs that have already been approved by regulators.

12) GLP-1 drugs such as Ozempic are showing significant capabilities to reduce obesity, and related diabetes and cardiovascular disease. Potential further uses under research include treating cancer, Parkinson’s disease and Alzheimer’s disease.

Source: Plunkett Research, Ltd.

Internet Research Tip:

For the latest biotech developments check out www.biospace.com, a private sector portal for the biotech community, and www.bio.org, the web site of the highly regarded Biotechnology Industry Organization.

WE PROFILE HUNDREDS OF TOP COMPANIES:

See All

PLUNKETT PROVIDES IN-DEPTH STATISTICS TABLES COVERING THE FOLLOWING INDUSTRY TOPICS:

Top Companies Profiled

The following is a partial listing for this industry. As a subscriber, you will have access to the leading companies and top growth companies. This includes publicly-held, private, subsidiary and joint venture companies, on a global basis as well as in the U.S.

Hundreds of Top Companies Profiled, Including:

PLUNKETT PROVIDES UNIQUE ANALYSIS OF THE FOLLOWING TRENDS THAT ARE DRIVING THIS INDUSTRY:

Key Findings:

A complete market research report, including forecasts and market estimates, technologies analysis and developments at innovative firms within the Biotech, Pharmaceuticals & Genetics Industry.Gain vital insights that can help shape strategy for business development, product development and investments.

Key Features:

Business trends analysis
In-depth industry overview
Technology trends analysis
Forecasts
Spending, investment, and consumption discussions
In-depth industry statistics and metrics
Industry employment numbers

Additional Key Features Include:

Industry Glossary

Industry Contacts list, including Professional Societies and Industry Associations

Profiles of industry-leading companies

U.S. and Global Firms
Publicly held, Private and Subsidiaries
Executive Contacts
Revenues
For Public Companies: Detailed Financial Summaries
Statistical Tables

Key Questions Answered Include:

How is the industry evolving?
How is the industry being shaped by new technologies?
How is demand growing in emerging markets and mature economies?
What is the size of the market now and in the future?
What are the financial results of the leading companies?
What are the names and titles of top executives?
What are the top companies and what are their revenues?

This feature-rich report covers competitive intelligence, market research and business analysis—everything you need to know about the Biotech, Pharmaceuticals & Genetics Industry.

Plunkett Research Provides Unique Analysis of the Following Major Trends Affecting the Biotech, Pharmaceuticals & Genetics Industry

Major Trends Affecting the Biotech, Pharmaceuticals & Genetics Industry
The State of the Biotechnology Industry Today
A Short History of Biotechnology
Fast Track Drugs Come to Market in the U.S. with FDA Cooperation
Ethanol Production Is Massive for Fuel Additives
Cellulosic Ethanol Makes Slow Commercial Progress
Major Drug Companies Acquire or Partner With Smaller Biotech Firms
Pharmaceutical R&D Improves with Artificial Intelligence (AI)
Nations Compete Fiercely in Biotech Development
Patients’ Genetic Profiles Plummet in Price as DNA Sequencing Technologies Advance
Gene Therapies Target Defective Genes/CRISPR Advances DNA Editing
Vaccines & Viruses as Therapies/mRNA Shows Great Promise
Massive R&D Investment Required for Development and Approval of New Drugs/Drug Prices Soar
Generic Drugs Have Biggest Market Share by Unit Volume, but not by Total Revenues
America Pays Higher Prices for Drugs Than Other Nations/U.S. Government Launches Drug Price Negotiation and Control Powers for Medicare
Biotech and Orphan Drugs Create New Revenues for Drug Firms
Revolutionary New Drugs (Zepbound, Wegovy and Ozempic) Treat Obesity, Diabetes and Addiction/Show Promise for Treating Many Other Diseases
Biosimilars (Generic Biotech Drugs) Receive FDA Guidelines for Accelerated Approval/Competition Will Be Fierce
Market for CBD Remains Steady
Stem Cells and 3-D Printing—A New Era of Tissue Replacement Takes Shape
Genetically Modified (GM) Seeds and Crops Planted in Dozens of Nations/Agribio R&D Investment Is High
Genetically Modified (GM) Foods Prompt Controversy, Labeling and Legislation
Plant-Based Meat Substitutes Developed
Selective Plant Breeding, Mutagenesis and Gene-Editing, Including CRISPR, as Alternatives to GM Seeds
Immunotherapy, ADCs and CAR-T Create Exciting New Approach to Fighting Cancers
Technology Discussion—Genes and DNA
Technology Discussion—Proteins and Proteomics
Technology Discussion—DNA Chips
Technology Discussion—SNPs (“Snips”)
Technology Discussion—Synthetic Biology
Technology Discussion—Recombinant DNA
Technology Discussion—Polymerase Chain Reaction (PCR)

Plunkett Research Provides In-Depth Tables for the Following Biotech, Pharmaceuticals & Genetics Industry Statistics

Biotech IndustryStatistics and Market Size Overview
The U.S. Drug Discovery & Approval Process
U.S. FDA Novel New Drug Approvals by Year 2015-2024
Employment in Life & Physical Science Occupations by Business Type, U.S.: May 2024
Federal R&D & R&D Funding for Basic Research, U.S.: Fiscal Years 2023-2025
U.S. Exports & Imports of Pharmaceutical Products: 2019-2024
Prescription Drug Expenditures & Annual Percent Change, U.S.: 2017-2033
NSF Budget by Appropriation (Dollars in Millions), Fiscal Years: 2023-2025
Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Years 2024-2026
The Nation's Health Dollar: 2025 Where It Came From (Projected)
The Nation's Health Dollar: 2025 Where It Went (Estimated)

Organizations that have used our research and products

Subscribe to Database: All industries
$2,495.00yearly, single userPRO, All Industries, With Exports, 1 User
$6,995.00yearly, 5 usersPRO TEAM, All Industries, With Exports, 5 Users
Add To Cart Multi-User Online, Enterprise-Wide (Library or Corporate) Request a Quote and Free Trial

Subscribe to Database: All industries
$2,495.00yearly, single user
$6,995.00yearly, 5 users
Add To Cart Multi-User Online, Enterprise-Wide (Library or Corporate) Request a Quote and Free Trial
eBook or Book: This industry onlyPublication date: Sep 2025
$399.99eBook, Single User (instant download)ISBN-13: 978-1-64788-576-2
$1,995.00eBook, Enterprise-Wide Use (instant download)
$399.99Printed AlmanacISBN-13: 978-1-64788-084-2

Format

Custom Research Projects

What data challenge can we help you solve today?

Data Needed:*

First Name:*

Last Name:*

Email Address:*

Country:

Organization:

Job Title:

Yes, Plunkett Research may email me Privacy Policy

Biotechnology, Pharmaceuticals & Genetics Industry Market Research

Biotechnology, Pharmaceuticals & Genetics OVERVIEW

WE PROFILE HUNDREDS OF TOP COMPANIES:

PLUNKETT PROVIDES IN-DEPTH STATISTICS TABLES COVERING THE FOLLOWING INDUSTRY TOPICS:

Top Companies Profiled

The following is a partial listing for this industry. As a subscriber, you will have access to the leading companies and top growth companies. This includes publicly-held, private, subsidiary and joint venture companies, on a global basis as well as in the U.S.

Hundreds of Top Companies Profiled, Including:

PLUNKETT PROVIDES UNIQUE ANALYSIS OF THE FOLLOWING TRENDS THAT ARE DRIVING THIS INDUSTRY:

Organizations that have used our research and products

CUSTOM MARKET RESEARCH

INDUSTRIES WE COVER

INDUSTRY ANALYTICS REPORTS

CORPORATE BENCHMARKS REPORTS

Related Products

Subscribe to Database:

Multi-User Online, Enterprise-Wide (Library or Corporate)

Subscribe to Database:

Multi-User Online, Enterprise-Wide (Library or Corporate)

eBook or Book:

What data challenge can we help you solve today?

Testimonials